Marinus Pharmaceuticals Inc
WKN: A2QEUC / ISIN: US56854Q2003Marinus Pharmaceuticals Buy KZ 16 USD
Jüngstes unrühmliches Beispiel , s.a. MiraGen (Kurs gestern/heute).
;-)
positive Phase3 Ganaxolone Studienergebnisse
https://endpts.com/...itive-phiii-readout-arrives-for-a-rare-disease/
1/4 Reverse Split
https://seekingalpha.com/news/3616107-marinus-reverse-split-shares-1-4
70 Mio. $ Offering
- 5 Mio. neue Aktien + Option auf weitere 15%
https://seekingalpha.com/news/...announces-pricing-of-equity-offering
Zahlen für 2020
https://www.sec.gov/Archives/edgar/data/1267813/...19095d1_ex99-1.htm
https://ir.marinuspharma.com/news/news-details/...esults/default.aspx
Verzögerung bei Phase-3-Studie RAISE Studie
- soll nun voraussichtlich in der zweiten Hälfte des Jahres 2023 abgeschlossen werden
https://ir.marinuspharma.com/news/news-details/...Trials/default.aspx
FDA Zulassung für ZTALMY/ganaxolone (in CDD)
"The FDA reviewed ZTALMY under Priority Review and granted ZTALMY orphan drug and Rare Pediatric Disease designations for the treatment of CDD. With the approval, the FDA awarded a Rare Pediatric Disease Priority Review Voucher (PRV), which Marinus plans to monetize."
https://ir.marinuspharma.com/news/news-details/...sorder/default.aspx
Im Tageshoch sogar über 12$.
https://ir.marinuspharma.com/news/news-details/...illion/default.aspx
https://ir.marinuspharma.com/news/news-details/...-China/default.aspx
Zahlen für Q2/24
- Umsatz 8 Mio. $
- Verlust 36 Mio. $
- Cash 65 Mio. $
- MK 91 Mio. $
- Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024
https://ir.marinuspharma.com/news/news-details/...esults/default.aspx
Studienflop
https://www.fiercepharma.com/pharma/...nother-ztalmy-trial-miss-sends
Immedica übernimmt Marinus
- für 0,55$ Cash je Aktie
https://ir.marinuspharma.com/news/news-details/...ls-Inc/default.aspx
1
|